Urothelial Carcinoma

TOMBOLA: Preliminary Results Show Promise for ctDNA-Guided Immunotherapy for Patients With MIBC

Researchers find promise for ctDNA-guided immunotherapy for patients with MIBC who underwent radical cystectomy.

Latest News

From Detection to Decision: The Future of Bladder Cancer Follow-Up

Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025

The panel concludes with a discussion on the complexities of interpreting ctDNA positivity in earlier-stage bladder cancer.

Bladder Preservation and Precision: Biomarkers Guiding the Future

Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025

The panel considers the adoption of bladder-sparing protocols and the potential of biomarkers to guide risk stratification.

Rethinking Risk: When to Repeat TURBT in Complex Bladder Cancer Cases

Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025

The panel debates the management of high-grade T1 bladder cancer with lymphovascular invasion and variant histology.

Striking the Balance: Efficacy Versus Toxicity in BCG-Unresponsive Bladder Cancer

Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025

The panel pivots to complex considerations in bladder cancer treatment, weighing the promise of IO in BCG-naïve patients.

Addressing the BCG Shortage: Impact on Practice and Patient Care

Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025

The panel shares how patient lifestyle, bladder symptoms, and other factors influence intravesical therapy selection.

Balancing Efficiency and Efficacy: Navigating Sequential Versus Combination Therapy

Sia Daneshmand, MDUrothelial Carcinoma | May 8, 2025

The panel explores the challenges of delivering bladder-sparing therapies like gem/doce and TAR-200 in real-world settings.

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Advanced Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma Diagnostics

Advanced Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Conference Coverage

Dr. David Canes on WellPrept - Boosting Patient Education and Improving Care

David Canes, MDUrothelial Carcinoma | May 7, 2025

Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.

Guidelines for Measuring Patient Outcomes and Quality Improvements in GU Oncology

Mohummad Siddiqui, MDUrothelial Carcinoma | May 5, 2025

Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.

ctDNA in GU Oncology: History, Current Studies, and Benefits

John Sfakianos, MDUrothelial Carcinoma Diagnostics | May 5, 2025

John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.

cT1a and cT1b-cT2 RCC: Who is at Risk of Upstaging to pT3a?

Victor Sandoval, MD, MScLocalized Renal Cell Carcinoma | May 5, 2025

Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.

Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection

Simpa Salami, MD, MPHProstate Cancer Diagnostics | May 5, 2025

Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.

Exploring Survival Outcomes of nccRCC With Tumor Thrombus Extension

Joseph Cheaib, MDnccRCC | May 5, 2025

Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.